BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 33906146)

  • 1. Endocrine dysfunction induced by immune checkpoint inhibitors.
    Deligiannis NG; Sosa S; Danilowicz K; Rizzo LFL
    Medicina (B Aires); 2021; 81(2):269-278. PubMed ID: 33906146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management.
    Del Rivero J; Cordes LM; Klubo-Gwiezdzinska J; Madan RA; Nieman LK; Gulley JL
    Oncologist; 2020 Apr; 25(4):290-300. PubMed ID: 32297436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint inhibitors and endocrine side effects, a narrative review.
    Agrawal L; Bacal A; Jain S; Singh V; Emanuele N; Emanuele M; Meah F
    Postgrad Med; 2020 Mar; 132(2):206-214. PubMed ID: 31876444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.
    Chang LS; Barroso-Sousa R; Tolaney SM; Hodi FS; Kaiser UB; Min L
    Endocr Rev; 2019 Feb; 40(1):17-65. PubMed ID: 30184160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How we treat endocrine complications of immune checkpoint inhibitors.
    Paschou SA; Stefanaki K; Psaltopoulou T; Liontos M; Koutsoukos K; Zagouri F; Lambrinoudaki I; Dimopoulos MA
    ESMO Open; 2021 Feb; 6(1):100011. PubMed ID: 33399077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review.
    Joshi MN; Whitelaw BC; Palomar MT; Wu Y; Carroll PV
    Clin Endocrinol (Oxf); 2016 Sep; 85(3):331-9. PubMed ID: 26998595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocrine immune-related adverse effects of immune-checkpoint inhibitors.
    Trevisani V; Iughetti L; Lucaccioni L; Predieri B
    Expert Rev Endocrinol Metab; 2023; 18(5):441-451. PubMed ID: 37682107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine immune-related adverse events: Adrenal, parathyroid, diabetes insipidus, and lipoatrophy.
    Atkinson M; Lansdown AJ
    Best Pract Res Clin Endocrinol Metab; 2022 May; 36(3):101635. PubMed ID: 35382989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitor-related hypophysitis.
    Mizukoshi T; Fukuoka H; Takahashi Y
    Best Pract Res Clin Endocrinol Metab; 2022 May; 36(3):101668. PubMed ID: 35562229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pituitary and adrenal disorders induced by immune checkpoint inhibitors.
    Albarel F; Brue T; Castinetti F
    Ann Endocrinol (Paris); 2023 May; 84(3):339-345. PubMed ID: 36965852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocrine side effects induced by immune checkpoint inhibitors.
    Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint inhibitor therapy-induced hypophysitis ∼ a case series of Taiwanese patients.
    Lin CH; Chen KH; Chen KY; Shih SR; Lu JY
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 3):524-529. PubMed ID: 30104119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies.
    Ferrari SM; Fallahi P; Elia G; Ragusa F; Ruffilli I; Patrizio A; Galdiero MR; Baldini E; Ulisse S; Marone G; Antonelli A
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Endocrinopathies Associated with Immune Checkpoint Inhibitors].
    Santos MJ
    Acta Med Port; 2022 Mar; 35(3):209-215. PubMed ID: 35077347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrine toxicities of immune checkpoint inhibitors.
    Wright JJ; Powers AC; Johnson DB
    Nat Rev Endocrinol; 2021 Jul; 17(7):389-399. PubMed ID: 33875857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocrine Adverse Events Caused by Different Types and Different Doses of Immune Checkpoint Inhibitors in the Treatment of Solid Tumors: A Meta-Analysis and Systematic Review.
    Yang Y; Liu J; Yang K; Ma Y; Fu S; Tang X; Wang Y; Zhou L
    J Clin Pharmacol; 2021 Mar; 61(3):282-297. PubMed ID: 33345342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Characteristics, Management, and Potential Biomarkers of Endocrine Dysfunction Induced by Immune Checkpoint Inhibitors.
    Iwama S; Kobayashi T; Arima H
    Endocrinol Metab (Seoul); 2021 Apr; 36(2):312-321. PubMed ID: 33934588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocrine adverse events related with immune checkpoint inhibitors: an update for clinicians.
    Deligiorgi MV; Panayiotidis MI; Trafalis DT
    Immunotherapy; 2020 May; 12(7):481-510. PubMed ID: 32345074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocrine Dysfunction From Immune Checkpoint Inhibitors: Pearls and Pitfalls in Evaluation and Management.
    Kotwal A; Perlman JE; Goldner WS; Marr A; Mammen JS
    JCO Oncol Pract; 2023 Jul; 19(7):395-402. PubMed ID: 37023383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. French Endocrine Society Guidance on endocrine side effects of immunotherapy.
    Castinetti F; Albarel F; Archambeaud F; Bertherat J; Bouillet B; Buffier P; Briet C; Cariou B; Caron P; Chabre O; Chanson P; Cortet C; Do Cao C; Drui D; Haissaguerre M; Hescot S; Illouz F; Kuhn E; Lahlou N; Merlen E; Raverot V; Smati S; Verges B; Borson-Chazot F
    Endocr Relat Cancer; 2019 Feb; 26(2):G1-G18. PubMed ID: 30400055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.